-
Affiliation
-
Faculty of Pharmacy, Department of Pharmacy 化学療法学講座 (Shiba-Kyoritsu)
-
Position
-
Professor
-
Related Websites
![]() KEIO RESEARCHERS INFORMATION SYSTEM |
Details of a Researcher
このページはJavascriptを使用しています。すべての機能を使用するためにはJavascript を有効にする必要があります。
Sugimoto, Yoshikazu
|
|
The University of Tokyo, Faculty of Pharmaceutical Science, 薬学科
University, Graduated
The University of Tokyo, Graduate School of Pharmaceutical Sciences, 生命薬学専攻
Graduate School, Completed, Doctoral course
Life Science / Clinical pharmacy (Clinical Pharmaceutical Science)
ABC transporter
molecular targer therapy
anticancer drug resistance
gene therapy
がん化学療法・分子標的治療update.
杉本芳一., 中外医学社, 東京, 2009.10
Scope: 59-63
がん薬物療法学.
杉本芳一., 大阪/日本臨床社, 2009.01
Scope: 349-355
がんの分子標的治療.
'野口耕司, 杉本芳一.', 東京/南山堂, 2008.09
Scope: 278-290
薬剤師生涯研修ガイド.
杉本芳一., 東京/学校法人医学アカデミー出版部, 2008.05
Scope: 223-224
薬学の未来を拓く.
杉本芳一., 東京/慶應義塾, 2008.04
Scope: 72-81
Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.
Yamatani K, Ai T, Saito K, Suzuki K, Hori A, Kinjo S, Ikeo K, Ruvolo V, Zhang W, Mak PY, Kaczkowski B, Harada H, Katayama K, Sugimoto Y, Myslinski J, Hato T, Miida T, Konopleva M, Hayashizaki Y, Carter BZ, Tabe T, Andreeff M.
Translational Oncology 18 101354 2022.01
Research paper (scientific journal), Joint Work, Accepted
Lu X., Yan G., Dawood M., Klauck S.M., Sugimoto Y., Klinger A., Fleischer E., Shan L., Efferth T.
Biochemical Pharmacology 194 114677 2021.12
Research paper (scientific journal), Joint Work, Accepted, ISSN 00062952
Lu X., Yan G., Klauck S.M., Fleischer E., Klinger A., Sugimoto Y., Shan L., Efferth T.
Biochemical Pharmacology 193 114788 2021.11
Research paper (scientific journal), Joint Work, Accepted, ISSN 00062952
Hegazy M.E.F., Dawood M., Mahmoud N., Elbadawi M., Sugimoto Y., Klauck S.M., Mohamed N., Efferth T.
Phytomedicine (Phytomedicine) 81 153409 2021.01
Research paper (scientific journal), Joint Work, Accepted, ISSN 09447113
GZD824 inhibits GCN2 and sensitizes cancer cells to amino acid starvation stress
Kato Y., Kunimasa K., Takahashi M., Harada A., Nagasawa I., Osawa M., Sugimoto Y., Tomida A.
Molecular Pharmacology 98 ( 6 ) 669 - 676 2020.12
Research paper (scientific journal), Joint Work, Accepted, ISSN 0026895X
Sugimoto, Yoshikazu
科学研究費補助金研究成果報告書 2014
Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics.
Noguchi K, Katayama K, Sugimoto Y*.
Pharmacogenomics and Personalized Medicine (Dove medical Press) 7 53-64 2014.02
Article, review, commentary, editorial, etc. (scientific journal), Joint Work
トランスポーターの遺伝子多型.
杉本芳一.
がん分子標的治療 (メディカルレビュー社) 9(3) 29-35 2011.07
Article, review, commentary, editorial, etc. (scientific journal), Single Work
分子標的薬.
杉本芳一.
薬局 (南山堂) 61(2) 11 2010.02
Article, review, commentary, editorial, etc. (scientific journal), Single Work
抗悪性腫瘍薬の薬理学・薬力学・薬理遺伝学ー薬物相互作用.
杉本芳一.
日本臨床 (日本臨床社) 67, Suppl 1 349-355 2009.01
Article, review, commentary, editorial, etc. (scientific journal), Single Work
抗癌剤開発における民族差について.
杉本芳一.
臨床評価 (/臨床評価刊行会) 33(2) 393-398 2006.04
Article, review, commentary, editorial, etc. (scientific journal), Single Work
カチオニック修飾はdextranにBCRP阻害効果を付与する
森本かおり, 石井敬, 杉本芳一, 荻原琢男, 富田幹雄.
日本薬物動態学会第36回年会,
Poster presentation
WEE1阻害薬耐性細胞におけるAKTの活性化
奥田賢, 近藤慎吾, 加藤優, 杉本芳一.
第65回日本薬学会関東支部大会,
Oral presentation (general)
Side population細胞に対するepigenetic阻害薬の効果
春名俊志, 加藤優, 近藤慎吾, 杉本芳一.
第65回日本薬学会関東支部大会,
Oral presentation (general)
エピジェネティック阻害剤によるSP細胞形質の抑制
加藤優, 近藤慎吾, 杉本芳一.
第25回日本がん分子標的治療学会学術集会,
Oral presentation (general)
FLT3-ITDによるintegrated stress response の誘導
佐々木大河, 加藤優, 片山和浩, 近藤慎吾, 杉本芳一
日本薬学会第141回年会,
Poster presentation
複数のがん分子標的治療薬の効果を左右する薬剤耐性・感受性規定因子の統合的研究
MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator
Analysis of the resistance mechanisms to molecular-targeting anticancer agents
MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator
Identification of factors regulating the capacity for both self-renewal and pluripotent differentiation of cancer stem cells and application to cancer treatment.
MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Challenging Exploratory Research, Principal investigator
STUDY OF MAJOR FIELD: (CHEMOTHERAPY)
2022
SEMINAR: (CHEMOTHERAPY)
2022
RESEARCH FOR BACHELOR'S THESIS 1
2022
PHARMACEUTICAL-ENGLISH SEMINAR
2022
PHARMACEUTICAL SCIENCES OF DISEASES
2022